Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in HFpEF (PIROUETTE)
NCT02932566Phase 2Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Extracellular volume fraction at 12 months. Started Mar 2017; status: completed.
02
Drugs
pirfenidone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02932566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932566.